NCT02708771View on ClinicalTrials.gov

Effect of W-3 Polyunsaturated Fatty Acids on Serum Albumin Concentration in Patients With Acute Heart Failure, Hypoalbuminemia, and High Inflammatory Activity

PHASE3CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
Heart Failure
Interventions
DRUG

Polyunsaturated fatty acids omega-3

4 daily capsules of polyunsaturated fatty acids omega-3, during 4 weeks. Each capsule contains: 460 mg eicosapentaenoic acid ethyl ester and 380 mg docosahexaenoic acid ethyl ester.

DRUG

Placebo

4 daily capsules of similar appearance and flavor without active ingredient

Trial Locations (1)

23400

Hospital San Juan de la Cruz, Úbeda

All Listed Sponsors
lead

Hospital San Juan de la Cruz

OTHER

NCT02708771 - Effect of W-3 Polyunsaturated Fatty Acids on Serum Albumin Concentration in Patients With Acute Heart Failure, Hypoalbuminemia, and High Inflammatory Activity | Biotech Hunter | Biotech Hunter